US-Listed Public Company Profile built from SEC and market records · June 2026

BIOMARIN PHARMACEUTICAL INC (BMRN)

$55.75 -0.36% NASDAQ: BMRN · 15-min delayed

NOVATO, California
Public · NASDAQ: BMRN
3,221 employees
Founded 1997

Visit website Follow

$11.5BMarket cap

$3.2BRevenue · FY2025

$348.9MNet income

3,221Employees

BMRNNASDAQ

1999IPO

About BIOMARIN PHARMACEUTICAL INC

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Company facts

Founded: 1997
Type: Public · NASDAQ: BMRN
Employees: 3,221
IPO date: Jul 23, 1999
Headquarters: 105 DIGITAL DRIVE
NOVATO, California 94949
Phone: (415) 506-6700
Industry: Pharmaceuticals
Website: Visit site

Incorporation record

Incorporated in: DE, United States
Registered office: Wilmington, US
Legal entity ID: NSLL8ITTRR0J5HEMR848

Source: GLEIF, the global Legal Entity Identifier registry · checked Jul 26, 2026. A US headquarters does not always mean US incorporation.

Registry IDs

Ticker: BMRN Nasdaq
SEC CIK: 1048477
LEI: NSLL8ITTRR0J5HEMR848
EIN: 680397820
SIC: 2834 PHARMACEUTICAL PREPARATIONS

Explore our data studies: the biggest company in every US state · all rankings & reports.

Embed this company’s badge

Show Biomarin Pharmaceutical Inc’s American-company profile badge on a website — copy this HTML:

<a href="https://americancompanies.com/company/biomarin-pharmaceutical-inc/"><img src="https://americancompanies.com/badge/biomarin-pharmaceutical-inc.svg" alt="Biomarin Pharmaceutical Inc — American company profile on americancompanies.com" width="220"></a>

Is this your company?

This profile is unclaimed — any authorized owner can claim it free, control the page, and activate the embeddable Verified badge for their own website.

Claim this profile — free

Track American companies

Create a free account to follow BIOMARIN PHARMACEUTICAL INC and get an email when it moves sharply — real market data, 15-minute delayed.

Create free account

Reported figures

Financial summary

Revenue FY2025: $3.2B
Net income: $348.9M
Total assets: $7.6B
Market cap: $11.5B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: BMRN

$55.75 -0.36%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$49.67 $70.24

52-week range

Market cap: $11.5B
Shares outstanding: 205.7M
Open: —
Day range: –
Prev close: —
Volume: —
IPO date: Jul 23, 1999

Biomarin Pharmaceutical Inc (BMRN) Stock Price

Profitable — net income of $348.9M in FY2025.
Trading 21% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review BIOMARIN PHARMACEUTICAL INC.

Write a review

Newsroom

News about BIOMARIN PHARMACEUTICAL INC

AC Original Inside America's Pharmaceutical Industry: Who's Building It A look at eight verified American pharmaceutical companies, from Illinois biotech giants to California gene-therapy inn… Jul 10, 2026

AC Original Inside America's Pharmaceutical Industry: The Companies Behind the Medicine Cabinet A look at eight verified American pharmaceutical companies, where they're based, and why domestic drugmakers matter to … Jul 8, 2026

AC Original Pharmaceuticals in America: A Guide to Verified U.S. Drug Makers An overview of America's pharmaceutical industry and eight independently verified companies, from Illinois giants to Ca… Jul 7, 2026

AC Original Pharmaceuticals in America: The Companies Behind the Nation's Medicine Cabinet A look at the American pharmaceutical sector and eight independently verified companies, from Illinois giants to coasta… Jul 7, 2026

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? Zacks Investment Research · 2026-10-19 · positive FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing Zacks Investment Research · 2026-10-07 · neutral Enzyme Replacement Therapy Market to Grow to USD 27.90 Billion by 2035 at a CAGR of 8.59% - SNS Insider GlobeNewswire Inc. · 2026-09-25 · positive BioMarin Stops Voxzogo Development for Noonan Syndrome Zacks Investment Research · 2026-09-16 · neutral How BioMarin Turned a Competitive Threat Into a Royalty-Bearing Asset Zacks Investment Research · 2026-09-03 · positive Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy GlobeNewswire Inc. · 2026-08-25 · positive

News & sentiment via Polygon.io

FAQ

Biomarin Pharmaceutical Inc: frequently asked questions

Is Biomarin Pharmaceutical Inc an American company?

Yes — Biomarin Pharmaceutical Inc is an American company headquartered in Novato, California. Its American-origin credentials have been independently reviewed and verified by americancompanies.com.

Where is Biomarin Pharmaceutical Inc headquartered?

Biomarin Pharmaceutical Inc is headquartered in Novato, California, United States.

Is Biomarin Pharmaceutical Inc publicly traded?

Yes — Biomarin Pharmaceutical Inc is a publicly traded company. Its stock trades under the ticker symbol BMRN on the NASDAQ.

What does Biomarin Pharmaceutical Inc do?

Biomarin Pharmaceutical Inc is an American Pharmaceuticals company in the Health & Beauty sector.

When was Biomarin Pharmaceutical Inc founded?

Biomarin Pharmaceutical Inc was founded in 1997.

Explore